Ligand Pharm Cmn (LGND) 106.38 $LGND Intec Pharma

New Post Public Reply Private Reply Replies (0) Message Board

Sep 1, 2016 at 3:05 PM

Ligand Pharm Cmn (LGND) 106.38 $LGND

Intec Pharma Reports First Half 2016 Financial Results
BusinessWire - Thu Sep 01, 5:00AM CDT
Intec Pharma Ltd. (Nasdaq: NTEC), a late stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill(TM) platform technology, reports financial results for the three and six months ended June 30, 2016.
NTEC: 6.25 (+0.21), LGND: 106.38 (+3.07)

Ligand Pharmaceuticals (LGND) Is in Oversold Territory: What's Next?
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 8:34AM CDT
Ligand Pharmaceuticals Incorporated (LGND) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
LGND: 106.38 (+3.07)

Ligand Pharmaceuticals is Now Oversold (LGND)
MarketNewsVideo.com - Wed Aug 17, 11:03AM CDT
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative...
LGND: 106.38 (+3.07)

Results from Phase 1 Trials with Ligand's LGD-6972 in Type 2 Diabetes Mellitus Published in Diabetes, Obesity and Metabolism
BusinessWire - Mon Aug 15, 8:00AM CDT
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) announces that results from two Phase 1 clinical trials with LGD-6972, the company's investigational glucagon receptor antagonist, were published online in the August issue of the journal Diabetes, Obesity and Metabolism. The article is available here.
LGND: 106.38 (+3.07)

Zacks.com featured highlights: Ligand Pharmaceuticals, Ormat Technologies, Activision Blizzard, Boise Cascade and Ubiquiti Networks
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 8:30AM CDT
Zacks.com featured highlights: Ligand Pharmaceuticals, Ormat Technologies, Activision Blizzard, Boise Cascade and Ubiquiti Networks
BCC: 26.03 (-0.21), ATVI: 42.12 (+0.75), ORA: 48.58 (+0.18), UBNT: 51.96 (+0.56), LGND: 106.38 (+3.07)

5 Stocks to Play Momentum the Driehaus Way
Zacks Equity Research - Zacks Investment Research - Thu Aug 11, 8:53AM CDT
Momentum strategies that have the potential to offer healthy returns have always been the on radar of investors with a high risk appetite.
BCC: 26.03 (-0.21), ATVI: 42.12 (+0.75), ORA: 48.58 (+0.18), UBNT: 51.96 (+0.56), LGND: 106.38 (+3.07)

Ligand Pharmaceuticals Falls 1.77% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Aug 09, 2:54PM CDT
Ligand Pharmaceuticals (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $115.00 to a high of $117.00. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $117.15 on volume of 315,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LGND: 106.38 (+3.07)

Inovio (INO) Q2 Loss in Line with Estimates, Revenues Top
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 8:41AM CDT
Inovio (INO) reported a loss of 26 cents per share in the second quarter of 2016, in line with the Zacks Consensus Estimate.
INO: 9.08 (-0.09), AZN: 32.63 (-0.18), LGND: 106.38 (+3.07), CORT: 5.31 (-0.02)

Endocyte (ECYT) Q2 Loss Wider than Expected (Revised)
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 4:31AM CDT
Endocyte (ECYT) reported a second-quarter 2016 loss of 33 cents per share, wider than the Zacks Consensus Estimate of a loss of 26 cents.
ECYT: 2.95 (-0.03), GERN: 2.71 (+0.02), LGND: 106.38 (+3.07), CORT: 5.31 (-0.02)

SmarTrend Watching for Potential Rebound in Shares of Ligand Pharmaceuticals After 6.49% Loss
Comtex SmarTrend(R) - Fri Aug 05, 1:23PM CDT
Ligand Pharmaceuticals (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $119.16 to a high of $130.06. Yesterday, the shares fell 6.5%, which took the trading range below the 3-day low of $131.02 on volume of 871,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LGND: 106.38 (+3.07)

Ligand (LGND) Q2 Earnings Decline Y/Y, Maintains View
Arpita Dutt - Zacks Investment Research - Fri Aug 05, 5:48AM CDT
Ligand (LGND) maintained its 2016 outlook for both earnings and revenues.
GILD: 77.20 (-1.18), GERN: 2.71 (+0.02), LGND: 106.38 (+3.07), ANIK: 47.82 (+0.58)

Ligand (LGND) Beats Q2 Earnings, Revenues Up Y/Y
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 8:41AM CDT
Ligand (LGND) maintained its track record by surpassing earnings expectations yet again.
LGND: 106.38 (+3.07)

Ligand Reports Second Quarter 2016 Financial Results
BusinessWire - Thu Aug 04, 7:00AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ended June 30, 2016, and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 9:00 a.m. Eastern time to discuss this announcement and answer questions.
LGND: 106.38 (+3.07)

Ligand (LGND) Q2 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Tue Aug 02, 6:18AM CDT
Our proven model does not conclusively show that Ligand (LGND) is likely to beat earnings estimates this quarter.
RPTP: 7.26 (-0.19), TECH: 106.84 (+1.49), LGND: 106.38 (+3.07), XLRN: 30.12 (+0.11)

Ligand Announces Multi-Program LTP Technology Licensing Agreement with Nucorion Pharmaceuticals
BusinessWire - Fri Jul 29, 7:30AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the signing of a license agreement for three programs utilizing Ligand's LTP (Liver Targeting Prodrug) technology with Nucorion Pharmaceuticals, Inc., a venture-funded biotechnology company focused on developing anti-cancer and anti-viral agents initially directed to China.
LGND: 106.38 (+3.07)

7 Profitable Medical Stocks Ranked as Buys Now
Arpita Dutt - Zacks Investment Research - Tue Jun 21, 2:52PM CDT
It may be tough going for medical stocks but these 7 companies sporting a favorable Zacks Rank are poised to generate profits this year.
ZTS: 50.87 (-0.23), JNJ: 118.90 (-0.44), PFE: 34.66 (-0.14), LGND: 106.38 (+3.07), BMY: 56.78 (-0.61), AMPH: 18.70 (-0.30)

7 Biotech Stocks that are Buys Right Now
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 10:00AM CDT
Buy these seven biotech stocks now and see how well the second half of 2016 unfolds for this industry.
MSTX: 0.53 (+0.09), RTRX: 16.27 (+0.25), AVEO: 0.92 (-0.01), SNSS: 0.84 (+0.03), LGND: 106.38 (+3.07), BIND: 0.78 (-0.09), ACOR: 24.21 (+0.13)

SmarTrend Watching for Potential Pullback in Shares of Ligand Pharmaceuticals After 1.08% Gain
Comtex SmarTrend(R) - Wed Jun 15, 3:13PM CDT
Ligand Pharmaceuticals (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $115.62 to a high of $117.18. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $116.07 on volume of 107,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
LGND: 106.38 (+3.07)

Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 9:52AM CDT
Lack of near-term pipeline catalysts, the MS franchise's performance, Tecfidera patent challenges and pipeline setbacks are some of the factors that are currently impacting Biogen (BIIB).
MACK: 4.58 (-0.04), BIIB: 305.80 (+0.17), IDRA: 1.87 (-0.04), RTRX: 16.27 (+0.25), LGND: 106.38 (+3.07), ACOR: 24.21 (+0.13)

Ligand (LGND) Tops Q1 Earnings, Revenues, Updates View
Arpita Dutt - Zacks Investment Research - Thu May 05, 8:36AM CDT
In addition to announcing first quarter results, Ligand (LGND) announced the acquisition of economic rights to several programs owned by CorMatrix.
CBM: 43.08 (+0.25), OMED: 10.16 (+0.17), LGND: 106.38 (+3.07), ANIK: 47.82 (+0.58)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Quay Sunglasses: Luxury Looks, Affordable Prices

Ah, sunglasses—the quintessential accessory that screams both practicality and style. A million-dollar look without the million-dollar expense? That's where Quay comes in. They've been recognized by Expert Consumers, no less, as some of the best-in-class for affordable luxury eye candy out there—aimed at shoppers who want the designer vibe without the hemorrhaging...

HONA Faces Legal Heat: Investor Lawsuit Over Losses

The Investor Storm Brewing Over Honeywell Aerospace There it is again, another industry heavyweight caught in a dizzying whirlwind of litigation. Honeywell Aerospace Inc. (NASDAQ:HONA), a name as established as an old boot in the business, now faces a class action lawsuit that's got investors frantically dusting off phone numbers for their attorneys. The Messy Allegations...

Farm Aid 2026: A Resilient Tribute to Family Farmers

Shining a Light on Essential Family Farmers Every year, thousands gather for Farm Aid to back the unsung heroes who put food on our plates. In 2026, the scene shifted to the amphitheater at Virginia Beach, where an epic lineup of music took stage not just to entertain but to underline a critical issue—family farmers are fighting for survival. These folks aren't merely...

Geron Corp Faces Fiduciary Duty Investigation

Spotlight on Geron's Corporate Governance: What's Happening? The heat's been turned up on Geron Corporation this week, with Halper Sadeh LLC, an investor rights law outfit, digging into whether some folks at the helm have strayed from their fiduciary duties to the shareholders. Now, if you're holding onto NASDAQ:GERN stock or thinking about diving in, it's high time to...

Krispy Kreme Faces Legal Probe: Fiduciary Breach?

Diving Deep into the Krispy Kreme Allegations Look, this isn't your run-of-the-mill donut drama. When you hear rumblings of corporate missteps, especially ones that involve potential breaches of fiduciary duties, it's time to perk up those ears. Over at Krispy Kreme, Inc. (NASDAQ:DNUT), there's some heat in the kitchen, and it's not just from frying those glazed beauties....

China Southern Airlines Marks 70th Anniversary in NYC

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...

Jackson Wang's Fantasy IP Hits Hong Kong Stage

A Star-Studded Fantasy Comes Alive Hong Kong isn't just about dim sum and skyline views—it's a magnet for celebrity showcases, and this time, Jackson Wang's pulling the strings. The guy's ventured beyond music and idol fame, diving head-first into creative visuals with his fantasy IP, "Under the Castle" (UTC). Pairing up with Ocean Park's Halloween Fest, he's cooked up...

PACS Group Faces Legal Scrutiny: What to Watch

PACS Group: Legal Storm Brewing Welcome to the latest saga in the volatile theater of corporate governance. PACS Group, Inc., ticker symbol NYSE:PACS, is under the microscope, and not for debuting a groundbreaking product or hitting a stock milestone. Nope, instead we've got Halper Sadeh LLC out of New York investigating some possible hanky-panky from PACS directors and...

Endurance Energy's Modular Tech Revs Up Southeast Asia

Modular Solutions Steal the Show in Bangkok When a company draws 59,468 attendees from over 150 countries, folks pay attention—and that was exactly the scene at Gastech 2026 in Bangkok. The name buzzing on many lips? Endurance Energy. These guys showcased a fresh take on energy logistics with their skid-mounted liquefaction tech, turning heads with their Southeast Asia...

CVS Health Under Fire: Fiduciary Duty Breach?

CVS Under Regulatory Spotlight for Fiduciary Breaches You'd think by now companies would have their fiduciary ducks in a row. But here we are, with CVS Health Corporation (NYSE: CVS) catching heat from the legal eagles over at Halper Sadeh LLC. The knife’s out for some of the big wigs – apparently, there's chatter they might’ve slipped on their duty to play nice...